[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Immix Biopharma, Inc. (IMMX) – Form 4 filed 06/23/2025

The filing discloses one transaction by Director and 10% owner Yekaterina (Katie) Chudnovsky dated 06/20/2025. She received a stock-option grant for 33,000 shares of common stock with an exercise price of $2.24 per share and an expiration date of 06/20/2035. The option vests in twelve equal monthly installments, contingent on continued board service. The option was acquired at no cost (transaction code “A”).

No non-derivative shares were bought or sold; the filing merely repeats her existing indirect ownership of 3,241,076 common shares held through GKCC, LLC, of which she is the sole member and manager. After the reported transaction, her total beneficial holdings stand at 3,241,076 shares (indirect) plus 33,000 derivative securities (direct).

Overall, the filing signals continued alignment between the director and shareholders through a sizeable existing stake and modest additional option incentives. The transaction does not materially alter the company’s share count or insider ownership structure.

Insights

Securities Analyst

TL;DR – Routine option grant; insider maintains 10% stake, no shares sold, neutral impact.

The 33,000-share option grant is standard board compensation and represents <1% of Immix’s 28 million basic shares outstanding (latest publicly reported). Chudnovsky’s pre-existing 3.24 million-share position—held via GKCC, LLC—remains unchanged, preserving her >10 % ownership status. No dispositions occurred, so there is no negative supply signal. The modest size of the grant, coupled with gradual vesting, limits near-term dilution pressure. From a governance standpoint, the filing confirms ongoing board engagement and provides fresh 10b5-1 disclosure checkboxes but introduces no new strategic information. Accordingly, the market impact is expected to be neutral.

Corporate Governance Expert

TL;DR – Compensation aligns incentives; nothing material beyond routine disclosure.

The option award extends through 2035, reinforcing long-term incentive alignment without immediate cash cost to the company. Twelve-month vesting encourages continued board participation, a positive governance signal, yet the scale is too small to meaningfully influence voting power or control. Because Chudnovsky already holds a significant equity stake, the incremental grant does not change control dynamics. The absence of sales or pledges reduces concerns about insider liquidity needs. No red flags noted, but likewise no catalyst for re-rating the stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chudnovsky Yekaterina

(Last) (First) (Middle)

C/O IMMIX BIOPHARMA, INC.

11400 WEST OLYMPIC BLVD., SUITE 200

(Street)

LOS ANGELES CA 90064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								3,241,076	I	Held by GKCC, LLC(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.24	06/20/2025		A		33,000		(2)	06/20/2035	Common Stock	33,000	$0.00	33,000	D

Explanation of Responses:

1. Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.

2. The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service on the Board of Directors.

	/s/ Yekaterina Chudnovsky	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Immix Biopharma (IMMX) report on 06/23/2025?

An option grant of 33,000 shares to Director/10% owner Yekaterina Chudnovsky dated 06/20/2025.

How many stock options were granted to Yekaterina Chudnovsky and at what price?

33,000 options with an exercise price of $2.24 per share.

When do the newly granted IMMX options expire?

They expire on 06/20/2035.

How many Immix Biopharma shares does Chudnovsky own after the transaction?

3,241,076 common shares held indirectly plus 33,000 options held directly.

Were any IMMX shares sold by the insider in this Form 4 filing?

No. The filing reports an acquisition of options only; no shares were sold.